| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M Reimold, C Solbach, S Noda, J-E Schaefer, M Bartels, M Beneke, H-J Machulla, R Bares, T Glaser, H Wormstal. Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology. vol 190. issue 2. 2007-03-30. PMID:17111172. |
occupancy of dopamine d(1), d (2) and serotonin (2a) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. |
2007-03-30 |
2023-08-12 |
Not clear |
| Philip Seema. Targeting the dopamine D2 receptor in schizophrenia. Expert opinion on therapeutic targets. vol 10. issue 4. 2007-03-13. PMID:16848689. |
of the various neurotransmitters, dopamine was the most potent in inhibiting the binding of [3h]haloperidol, indicating that the antipsychotic receptor was a dopamine receptor, now named the dopamine d2 receptor, a major targeting site in schizophrenia. |
2007-03-13 |
2023-08-12 |
Not clear |
| Sandra Schäble, Gerd Poeggel, Katharina Braun, Michael Grus. Long-term consequences of early experience on adult avoidance learning in female rats: role of the dopaminergic system. Neurobiology of learning and memory. vol 87. issue 1. 2007-02-22. PMID:16938473. |
in addition, the pharmacological blockade of dopamine receptors during preweaning avoidance training via systemic application of haloperidol impaired preweaning avoidance performance in a dose-dependent manner. |
2007-02-22 |
2023-08-12 |
rat |
| A Lazou, T Markou, M Zioga, E Vasara, A Efstathiou, C Gaitanak. Dopamine mimics the cardioprotective effect of ischemic preconditioning via activation of alpha1-adrenoceptors in the isolated rat heart. Physiological research. vol 55. issue 1. 2007-01-30. PMID:15857158. |
pretreatment with the mixed d1/d2 dopaminergic receptor antagonist haloperidol or the beta-adrenoceptor selective antagonist propranolol did not attenuate the protective effect of pharmacological preconditioning with 10 microm dopamine with respect to both functional recovery and infarct size reduction. |
2007-01-30 |
2023-08-12 |
rat |
| Hyeon Soo Kim, Minseok Song, Sanatombi Yumkham, Jang Hyun Choi, Taehoon Lee, Joseph Kwon, Sung Jae Lee, Jong-In Kim, Kang-Woo Lee, Pyung-Lim Han, Seung Woo Shin, Ja-Hyun Baik, Yong Sik Kim, Sung Ho Ryu, Pann-Ghill Su. Identification of a new functional target of haloperidol metabolite: implications for a receptor-independent role of 3-(4-fluorobenzoyl) propionic acid. Journal of neurochemistry. vol 99. issue 2. 2007-01-08. PMID:17029599. |
haloperidol, a dopamine d2 receptor blocker, is a classical neuroleptic drug that elicits extrapyramidal symptoms. |
2007-01-08 |
2023-08-12 |
mouse |
| Mahendra Bishnoi, Kanwaljit Chopra, Shrinivas K Kulkarn. Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes. European journal of pharmacology. vol 552. issue 1-3. 2007-01-04. PMID:17064683. |
on chronic administration of haloperidol there was a decrease in dopamine and norepinephrine turnover which was dose-dependently reversed by treatment with adenosine or caffeine. |
2007-01-04 |
2023-08-12 |
rat |
| A Fredriksson, T Arche. Subchronic administration of haloperidol influences the functional deficits of postnatal iron administration in mice. Neurotoxicity research. vol 10. issue 2. 2007-01-03. PMID:17062374. |
in the context of these and other observations, it is suggested that subchronic administration of haloperidol interacting with postnatal iron induces different expressions of dopamine neuron comorbidity underlying movement disorder. |
2007-01-03 |
2023-08-12 |
mouse |
| Huma Saeedi, Gary Remington, Bruce K Christense. Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood. Schizophrenia research. vol 85. issue 1-3. 2006-12-28. PMID:16679001. |
impact of haloperidol, a dopamine d2 antagonist, on cognition and mood. |
2006-12-28 |
2023-08-12 |
human |
| Dineshree V Naiker, Stanley V Catts, Vibeke S Catts, Kuldip S Bedi, Lesley J Bryan-Lluk. Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat. European journal of pharmacology. vol 540. issue 1-3. 2006-12-11. PMID:16730699. |
dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine d2-receptor occupancy method in the rat. |
2006-12-11 |
2023-08-12 |
rat |
| Dineshree V Naiker, Stanley V Catts, Vibeke S Catts, Kuldip S Bedi, Lesley J Bryan-Lluk. Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat. European journal of pharmacology. vol 540. issue 1-3. 2006-12-11. PMID:16730699. |
the purpose of the present study was to determine antipsychotic doses that achieve 80% striatal dopamine d2-receptor occupancy for haloperidol, risperidone and olanzapine in rats. |
2006-12-11 |
2023-08-12 |
rat |
| Dineshree V Naiker, Stanley V Catts, Vibeke S Catts, Kuldip S Bedi, Lesley J Bryan-Lluk. Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat. European journal of pharmacology. vol 540. issue 1-3. 2006-12-11. PMID:16730699. |
the doses required to achieve dopamine d2-receptor occupancy of 80% in 11- and 24-week old rats were: haloperidol 0.25 mg/kg/day, risperidone 5 mg/kg/day and olanzapine 10 mg/kg/day. |
2006-12-11 |
2023-08-12 |
rat |
| Ella H Sklan, Amit Berson, Klara R Birikh, Amos Gutnick, Or Shahar, Shai Shoham, Hermona Sore. Acetylcholinesterase modulates stress-induced motor responses through catalytic and noncatalytic properties. Biological psychiatry. vol 60. issue 7. 2006-11-07. PMID:16904653. |
more specifically, we induced stress-associated hypofunction of dopaminergic, mainly d2 dopamine receptor-mediated neurotransmission by haloperidol and explored stress induced hyperlocomotion and catalepsy, an extreme form of immobility, induced in mice with ache deficiencies. |
2006-11-07 |
2023-08-12 |
mouse |
| C R Maxwell, Y Liang, M P Kelly, S J Kanes, T Abel, S J Siege. Mice expressing constitutively active Gsalpha exhibit stimulus encoding deficits similar to those observed in schizophrenia patients. Neuroscience. vol 141. issue 3. 2006-10-18. PMID:16750890. |
n40 deficits in transgenic animals were ameliorated with low dose haloperidol and reversed with higher dose, suggesting dopamine d2 receptor-linked gi activity contributes to the impairment. |
2006-10-18 |
2023-08-12 |
mouse |
| Jeffrey B Eells, Jaime A Misler, Vera M Nikode. Reduced tyrosine hydroxylase and GTP cyclohydrolase mRNA expression, tyrosine hydroxylase activity, and associated neurochemical alterations in Nurr1-null heterozygous mice. Brain research bulletin. vol 70. issue 2. 2006-10-10. PMID:16782508. |
furthermore, dopamine levels in the striatum of +/- mice were significantly reduced after inhibition of dopamine synthesis or after haloperidol treatment but not under basal conditions while dopamine levels in the nucleus accumbens were reduced under basal conditions. |
2006-10-10 |
2023-08-12 |
mouse |
| Ellen R A de Bruijn, Bernard G C Sabbe, Wouter Hulstijn, Gé S F Ruigt, Robbert J Verke. Effects of antipsychotic and antidepressant drugs on action monitoring in healthy volunteers. Brain research. vol 1105. issue 1. 2006-09-29. PMID:16499887. |
the attenuated erns after the dopamine antagonist haloperidol are in line with the presumed role of dopamine in action monitoring. |
2006-09-29 |
2023-08-12 |
human |
| Tim Karl, Liesl Duffy, Elizabeth O'brien, Izuru Matsumoto, Irina Dedov. Behavioural effects of chronic haloperidol and risperidone treatment in rats. Behavioural brain research. vol 171. issue 2. 2006-09-25. PMID:16697060. |
the therapeutic properties of typical antipsychotic drugs (apds) such as haloperidol in schizophrenia treatment are mainly associated with their ability to block dopamine d2 receptors. |
2006-09-25 |
2023-08-12 |
rat |
| S J Chrapusta, M F Ega. Poor evidence for depolarization block but uncoupling of nigral from striatal dopamine metabolism after chronic haloperidol treatment in the rat. Journal of neural transmission (Vienna, Austria : 1996). vol 113. issue 5. 2006-09-19. PMID:16082510. |
poor evidence for depolarization block but uncoupling of nigral from striatal dopamine metabolism after chronic haloperidol treatment in the rat. |
2006-09-19 |
2023-08-12 |
rat |
| S J Chrapusta, M F Ega. Poor evidence for depolarization block but uncoupling of nigral from striatal dopamine metabolism after chronic haloperidol treatment in the rat. Journal of neural transmission (Vienna, Austria : 1996). vol 113. issue 5. 2006-09-19. PMID:16082510. |
chronic haloperidol treatment induces depolarization block in midbrain dopamine neuronal systems. |
2006-09-19 |
2023-08-12 |
rat |
| S J Chrapusta, M F Ega. Poor evidence for depolarization block but uncoupling of nigral from striatal dopamine metabolism after chronic haloperidol treatment in the rat. Journal of neural transmission (Vienna, Austria : 1996). vol 113. issue 5. 2006-09-19. PMID:16082510. |
haloperidol pretreatment significantly modified haloperidol challenge effect on regional dopamine metabolite contents. |
2006-09-19 |
2023-08-12 |
rat |
| S J Chrapusta, M F Ega. Poor evidence for depolarization block but uncoupling of nigral from striatal dopamine metabolism after chronic haloperidol treatment in the rat. Journal of neural transmission (Vienna, Austria : 1996). vol 113. issue 5. 2006-09-19. PMID:16082510. |
these results suggest that chronic haloperidol treatment uncouples somatodendritic dopamine turnover and release from those in the axon terminals of nigrostriatal dopamine neurons. |
2006-09-19 |
2023-08-12 |
rat |